CAR-T therapy study for relapsed or treatment-resistant blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests CAR-T cell therapy (immune cells modified to target cancer) in people whose blood cancers came back or didn’t respond to standard treatments. If you qualify, the study aims to see whether this treatment can fight the cancer and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like lymphoma, myeloma, or leukemia) that returned or didn’t respond to standard treatment
- Your cancer has specific “target” antigens that the therapy is designed to recognize
- Your body can handle study procedures and you can follow up; you can understand the study and sign consent
- Your energy level is good (ECOG 0 to 2)
- Your main organs meet lab limits (liver, kidney, and other blood tests) including bilirubin, AST/ALT, creatinine, and BNP
- You do not have major exclusions like serious heart disease or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
Hear when a new Relapsed/Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.